CoChat

Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation

Slingerland, A. S., Hurkx, W., Noordam, K., Flanagan, S. E., Jukema, J. W., Meiners, L. C., Bruining, G. J., Hattersley, A. T., Hadders‐Algra, M. · 2008 · Diabetic Medicine
Cited by 112

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background KCNJ11 mutations are a common cause of diabetes diagnosed in the first 6 months of life, and approximately 25% of patients have neurological features. Sulphonylureas have been shown to improve glycaemic control and also motor function, but the impact on cognitive function has not been extensively addressed previously. Methods The patient had a low birth weight and was found to have diabetes at the age of 2 days. The patient was treated with insulin from diagnosis. The child also had marked developmental delay so that his average functional age was 2.5 years when he was 12 years old. A V59M mutation in KCNJ11 was found on sequencing, resulting in a diagnosis of intermediate developmental delay, epilepsy, neonatal diabetes (DEND) syndrome. Identification of a Kir6.2 mutation allowed insulin injections to be replaced by glibenclamide tablets. Results This resulted not only in improved glycaemic control (HbA 1c fell from 8.1 to 6.5%), but also an impressive improvement in many aspects of cognitive function, with the functional age increasing to 4 years within 6 months of treatment change. Conclusions This is the first clear report of cognitive function improving in a patient with the neurological features associated with a K ATP channel mutation following transfer to sulphonylureas. The finding of cognitive improvement suggests that glibenclamide is likely to be acting directly on the brain and not just on nerve and muscle, improving muscle strength.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2007.02373.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 112

Metadata

Authors
Slingerland, A. S., Hurkx, W., Noordam, K., Flanagan, S. E., Jukema, J. W., Meiners, L. C., Bruining, G. J., Hattersley, A. T., & Hadders‐Algra, M.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2008-02-27
Volume
25
Issue
3
Pages
277-281
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2145641198
Cited by
112
References
3
FWCI
10.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. https://app.cochat.ai/papers/10.1111/j.1464-5491.2007.02373.x
The paper
Slingerland, A. S., Hurkx, W., Noordam, K., Flanagan, S. E., Jukema, J. W., Meiners, L. C., Bruining, G. J., Hattersley, A. T., & Hadders‐Algra, M. (2008). Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2007.02373.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.